Category: Products & Tech

depomed_logo

Type 2 Diabetics May be Able to Tolerate Higher Doses of Metformin Using Glumetza

A press release issued today by Depomed, Inc. and Santarus, Inc says that according to the clinical trial results, patients previously intolerant of metformin may be able to tolerate higher efficacious doses of metformin when treated with GLUMETZA, with fewer gastrointestinal side effects. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes...
0 Shares
Amylin Lilly Logo

Byetta Helps Type 2 Diabetics Achieve Blood Glucose Control

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA(R) (exenatide) injection added to Lantus(R) (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing...
0 Shares
amylin logo

Symlin Does Not Increase Risk of Cardiovascular Event, New Study Shows

Amylin Pharmaceuticals, Inc. announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN(R) (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin...
0 Shares
Novo Nordisk Logo

Victoza Superior to Januvia, New Study Shows

Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia plus metformin at 52 weeks...
0 Shares
Novo Nordisk Logo

Novo Nordisk Presents Positive Phase 2 Data for Ultra-Long-Acting Insulin Degludec

According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando FL...
0 Shares

Abbott Receives FDA Clearance for New FreeStyle Test Strips

Following the recent clearance of its FreeStyle Lite® blood glucose test strips, Abbott announced that it has also received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new FreeStyle blood glucose test strips. The new FreeStyle test strips minimize interference during blood glucose testing and are designed to offer a better testing experience...
0 Shares
Abbott logo

Abbott Receives FDA Clearance for New FreeStyle Test Strips

Following the recent clearance of its FreeStyle Lite® blood glucose test strips, Abbott announced that it has also received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new FreeStyle blood glucose test strips. The new FreeStyle test strips minimize interference during blood glucose testing and are designed to offer a better testing experience...
0 Shares
Bristol-Myers Logo

Bristol-Myers Squibbs’ Dapagliflozin Demonstrated Improved Glycemic Control in Adults with Type 2 Diabetes

Bristol-Myers announced that findings from a 24-week Phase 3 clinical study, published online in the latest issue of Diabetes Care, demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of HbA1c levels...
0 Shares
EliLillyLogo

Eli Lilly and Walmart to Provide Affordable Insulin

Eli Lilly and Company announced they're teaming up with Walmart to provide an affordable insulin option for people with diabetes. Beginning in mid-September, Lilly's Humulin(R) brand of insulin will be available in Walmart pharmacies...
0 Shares